- Home
- NEUP vs ERNA Comparison
NEUP vs ERNA Comparison
Compare NEUP & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEUP
- ERNA
- Stock Information
- Founded
- NEUP 1996
- ERNA 2018
- Country
- NEUP United States
- ERNA United States
- Employees
- NEUP N/A
- ERNA N/A
- Industry
- NEUP
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- NEUP
- ERNA Health Care
- Exchange
- NEUP Nasdaq
- ERNA Nasdaq
- Market Cap
- NEUP 12.7M
- ERNA 13.5M
- IPO Year
- NEUP N/A
- ERNA N/A
- Fundamental
- Price
- NEUP $7.70
- ERNA $2.05
- Analyst Decision
- NEUP Strong Buy
- ERNA
- Analyst Count
- NEUP 1
- ERNA 0
- Target Price
- NEUP $21.00
- ERNA N/A
- AVG Volume (30 Days)
- NEUP 38.4K
- ERNA 95.7K
- Earning Date
- NEUP 08-15-2025
- ERNA 08-12-2025
- Dividend Yield
- NEUP N/A
- ERNA N/A
- EPS Growth
- NEUP N/A
- ERNA N/A
- EPS
- NEUP 0.00
- ERNA N/A
- Revenue
- NEUP $15,662,715.00
- ERNA $535,000.00
- Revenue This Year
- NEUP N/A
- ERNA N/A
- Revenue Next Year
- NEUP N/A
- ERNA N/A
- P/E Ratio
- NEUP $4,532.08
- ERNA N/A
- Revenue Growth
- NEUP N/A
- ERNA 365.22
- 52 Week Low
- NEUP $2.90
- ERNA $1.75
- 52 Week High
- NEUP $126.00
- ERNA $34.35
- Technical
- Relative Strength Index (RSI)
- NEUP N/A
- ERNA 39.29
- Support Level
- NEUP N/A
- ERNA $1.88
- Resistance Level
- NEUP N/A
- ERNA $2.12
- Average True Range (ATR)
- NEUP 0.00
- ERNA 0.13
- MACD
- NEUP 0.00
- ERNA 0.04
- Stochastic Oscillator
- NEUP 0.00
- ERNA 42.42
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.